Rigel Pharmaceuticals Showcases GAVRETO® Data for RET Fusion-Positive Cancers at ESMO Congress 2026 #United_States #South_San_Francisco #Rigel_Pharmaceuticals #GAVRETO #ESMO_Congress
@newsen.bsky.social
third-news.comRigel Pharmaceuticals Showcases GAVRETO® Data for RET Fusion-Positive Cancers at ESMO Congress 2026Rigel Pharmaceuticals presented significant findings on GAVRETO® for RET fusion-positive cancers at the 2026 ESMO Congress, highlighting treatment efficacy.